| Drug Name: | Trastuzumab (180288-69-1) |
|---|---|
| PubChem ID: | |
| SMILES: | CCCCN1C(=O)C(NC(=O)C12CCN(CC2)CC3=CC=C(C=C3)OC4=CC=C(C=C4)C(=O)O)C(C5CCCCC5)O |
| InchiKey: | GWNOTCOIYUNTQP-FQLXRVMXSA-N |
| Therapeutic Category: | Antineoplastic Agents |
| Molecular Weight (dalton) | : | 577.722 |
| LogP | : | 4.58 |
| Ring Count | : | 2 |
| Hydrogen Bond Acceptor Count | : | 6 |
| Hydrogen Bond Donor Count | : | 3 |
| Total Polar Surface Area | : | 119.41 |
This panel provides information on interacting drugs and their ADRs along with references
| Interacting drug | Toxicity | Interaction Type | Mechanism | Reference |
|---|
This panel provides drug-protein interaction and their ADRs along with references
| Toxicity | Interacting Protein | Mechanism | Reference |
|---|---|---|---|
| Tumor Suppression | Receptor tyrosine-protein kinase erbB-2 (P04626) | C-erbB-2 (HER2/neu) protein overexpression or amplification has been noted in some solid tumors a molecular target for tumor suppression [ ADR Type 2 ] | Clinical implications of trastuzumab |
This panel provides drug-food interactions and their ADRs along with references
| Food | Toxicity | Reference |
|---|
This panel provides information on metabolites and their ADRs along with references
| Metabolite | Toxicity | Place of Metabolism | Mechanism | Reference |
|---|
This panel provides information on drug category